In the Democratic Republic of Congo, a rare strain of Ebola called Bundibugyo is writing what may become one of the darkest chapters in the country's long and painful history with the virus. Since mid-May, 2,325 people have died — a toll surpassing every prior outbreak on Congolese soil — with the disease claiming a life every thirty minutes in a nation already worn by decades of conflict. Humanity now watches as scientists race to develop a vaccine for a strain so rare it has only appeared twice before in recorded history, while the WHO works against the clock to bend the curve of transmissio
DR Congo's Ebola outbreak becomes deadliest on record with 2,325 deaths
2,325 people have been killed by the Ebola outbreak in DR Congo, with the virus claiming one life every 30 minutes according to UN humanitarian officials.
Someone dies every 30 minutes from this virus
Mark
Why is this outbreak spreading so much faster than previous ones?
Mimi
The Bundibugyo strain itself may be more transmissible, but the real accelerant is the context. Six provinces, years of conflict, people constantly moving. You can't isolate communities when they're already fractured and mobile. The virus finds the gaps.
Mark
The vaccine situation sounds promising—Oxford already has the platform from Covid. How long until it's available?
Mimi
They've just started human trials. That's the first step. Even with an accelerated timeline, you're looking at months before you know if it works, then manufacturing at scale. Meanwhile, someone dies every 30 minutes.
Mark
Why is Bundibugyo so rare? What makes it different from other Ebola species?
Mimi
That's the unsettling part—we don't know much about it. Only two outbreaks before this one. It's rare enough that the medical world doesn't have deep experience with it. That uncertainty itself is a problem when you're trying to respond.
Mark
The WHO says they can reverse transmission in three months. Do you believe that?
Mimi
They're being careful with their language. Reverse transmission, not end it. That's realistic caution. But it depends entirely on whether vaccines work, whether treatments help, and whether the country can actually reach people in conflict zones. Three months is a target, not a promise.
Mark
What happens if the outbreak spreads beyond Uganda and those two cases in Europe?
Mimi
That's the real fear. Right now it's contained to the region, but Bundibugyo is novel enough that no one has immunity. If it reaches a major transit hub—a city with international flights—the calculus changes entirely. That's when it stops being a regional crisis.
Il Polso
- The Bundibugyo strain is spreading at a pace that has stunned global health officials — reaching 2,000 deaths in under three months, a threshold that took the catastrophic 2014 West African outbreak nearly five months to cross.
- With 4,945 confirmed cases across six provinces and 101 new infections recorded in a single day, the outbreak shows no sign of slowing, and the UN's humanitarian chief has warned the world in the starkest possible terms.
- No approved vaccine exists for this particular Ebola species, leaving health workers to rely on containment measures in a country where years of armed conflict and high population mobility have historically undermined every such effort.
- A glimmer of hope is emerging from laboratories: Oxford researchers have begun the first human trials of a Bundibugyo vaccine built on Covid-19 technology, while three other groups pursue their own candidates and the WHO tests antivirals inside Congo itself.
- The WHO has set a three-month target to reverse transmission — not to end the outbreak, but to bring it under control — a distinction that underscores just how difficult the road ahead remains.
In the Democratic Republic of Congo, a rare strain of Ebola called Bundibugyo is writing what may become one of the darkest chapters in the country's long and painful history with the virus. Since mid-May, 2,325 people have died — a toll surpassing every prior outbreak on Congolese soil — with the disease claiming a life every thirty minutes in a nation already worn by decades of conflict. Humanity now watches as scientists race to develop a vaccine for a strain so rare it has only appeared twice before in recorded history, while the WHO works against the clock to bend the curve of transmission within three months.
The Democratic Republic of Congo is now living through the deadliest Ebola outbreak in its history. Since the virus was identified on May 15, it has claimed 2,325 lives, surpassing the country's previous epidemic of 2018 to 2020. The culprit is Bundibugyo — an exceptionally rare strain with only two prior documented outbreaks anywhere in the world — and it is moving with a speed that has alarmed global health officials. The UN's humanitarian chief, Tom Fletcher, put it plainly: someone dies from this virus every thirty minutes.
The scale of acceleration is difficult to absorb. The West African epidemic of 2014 to 2016, the deadliest the world had previously seen, took nearly five months to reach 1,000 deaths. The current outbreak reached 2,000 in less than three. As of the latest count, Congo's Institute of Public Health has confirmed 4,945 cases across six of the country's 26 provinces, with 101 new infections recorded in a single day. The WHO has described the pace of transmission as exceptional. Beyond Congo's borders, Uganda has confirmed 20 cases, while Germany and France have each treated a small number of patients.
The structural challenges facing any response are formidable. Congo has endured generations of armed conflict, and its population moves frequently across vast distances — conditions that have historically made disease containment far harder. This is the country's 17th Ebola outbreak since the virus was first identified fifty years ago. Ebola progresses in stages, beginning with symptoms that can resemble flu or malaria before advancing to vomiting, diarrhea, and potentially organ failure. It spreads through contact with infected bodily fluids.
No approved vaccine exists for the Bundibugyo strain, but the scientific response is accelerating. The UK's medicines regulator has authorized the first human trials of a vaccine developed at the University of Oxford, built on the same platform that produced the Oxford-AstraZeneca Covid-19 vaccine. Three other research groups are pursuing separate candidates. Inside Congo, the WHO is sponsoring a clinical trial to determine whether existing antiviral drugs can improve survival rates.
The WHO has expressed hope of reversing the outbreak's trajectory within three months — though officials have been careful to note this means controlling transmission, not eliminating the disease entirely. In a country where conflict and mobility have long complicated public health, that distinction carries real weight. The race between the virus and the tools to stop it is very much still underway.
The Democratic Republic of Congo is now contending with the deadliest Ebola outbreak in its recorded history. Since the virus was identified on May 15, it has claimed 2,325 lives—a grim milestone that exceeds the toll from the country's previous epidemic between 2018 and 2020. The outbreak is caused by Bundibugyo, a particularly rare strain of the virus, and it is advancing with alarming speed.
The numbers alone convey the severity. As of the most recent count, the country's Institute of Public Health confirmed 4,945 cases, with 101 new infections recorded in a single 24-hour period. The UN's humanitarian chief, Tom Fletcher, described the situation last week in stark terms: someone dies from this virus every 30 minutes. To grasp how quickly this outbreak has moved, consider the comparison to history. The West African epidemic of 2014 to 2016, which was the deadliest the world had seen, took nearly five months to reach 1,000 deaths. The current outbreak reached 2,000 deaths in less than three months.
Bundibugyo itself is exceptionally uncommon. Only two prior outbreaks of this particular species have been documented in medical records. The virus has now spread across six of the country's 26 provinces, and the World Health Organization has characterized the pace of transmission as "exceptional." Beyond the borders, the international presence remains limited: Uganda has confirmed 20 cases, Germany treated two patients, and France recorded one case as of mid-August. The containment, so far, has largely held at the regional level.
The Democratic Republic of Congo faces structural obstacles that complicate any response. The country has endured years of conflict, and its population is highly mobile—both factors that historically have made disease control far more difficult. This is the 17th Ebola outbreak to emerge in the country since the virus was first identified 50 years ago. The disease itself progresses in stages. Initial symptoms—fever, headache, exhaustion—can appear within two to 21 days of infection and resemble flu or malaria. As it advances, patients develop vomiting and diarrhea, which can cascade into organ failure. The virus spreads through contact with infected bodily fluids, particularly blood and vomit.
No approved vaccine currently exists for Bundibugyo, but several candidates are in active development. The UK's medicines regulator has authorized the first human trials of a vaccine created by researchers at the University of Oxford, built on the same technological platform that produced the Oxford-AstraZeneca Covid-19 vaccine. Three additional research groups are pursuing separate vaccine candidates. Simultaneously, the WHO is sponsoring a clinical trial within the Democratic Republic of Congo to test whether two existing antiviral drugs can improve survival rates among infected patients.
The World Health Organization has stated it hopes to reverse the outbreak's trajectory within three months—though officials have been careful to clarify that this means bringing transmission under control, not eliminating the outbreak entirely. That distinction matters. Containment and eradication are different challenges, and in a country where conflict and population movement have long complicated public health efforts, the path forward remains uncertain. The race is on between the virus's spread and the development of tools to stop it.
Citazioni salienti
The epidemic is killing someone every 30 minutes— Tom Fletcher, UN humanitarian chief
The pace of the virus's transmission has been described as exceptional— World Health Organization
Vuoi la storia completa?
Leggi l'originale su BBC News ↗
Health & Medicine